MNMaarten Naesens

Maarten Naesens

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maarten Naesens has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Continuous Diagnostic Indices from BanffNET Automated Lesion Scores for Kidney Transplant Pathology: Development and Evaluation of a Diagnostic Prediction Model

    by Arthur Vranken, Giorgio Buzzanca, Thibaut Vaulet, Karolien Wellekens, Priyanka Koshy, Danny van der Helm, Soufian Meziyerh, Jan-Hendrik Venhuizen, Saskia Haitjema, Arjan D. van Zuilen, et al.

    Background: Histopathological diagnoses in kidney transplant biopsies, as described by the Banff classification, suffer from substantial inter-observer variability and misinterpretation, making them prone to diagnostic errors. Continuous indices based on BanffNET automated lesion scores are proposed to quantify the continuous phenotypic spectrum of kidney transplant biopsies, complementary to pathologist assessment of biopsies. Methods: The BanffNET model was used to obtain continuous lesion scoring for a training cohort of 2544 biopsies, a large validation cohort of 3863 biopsies, and a multi-reader cohort of 36 biopsies scored by 67 pathologists. A penalized regression approach was used to condense 17 automated lesion scores into four indices, representing the most important dimensions of graft injury: a TCMR/TI Index, an AMR/MVI Index, an Activity Index and a Chronicity Index. The BanffNET Indices were evaluated against Banff diagnoses and histological indices in the training cohort and validation cohort. Since pathologist-assigned Banff lesions and diagnoses suffer from inter-observer variability, associations were also assessed with diagnoses in a multi-reader study, with time to kidney graft failure in the training and validation cohort and with biopsy-based molecular signatures in the validation cohort. Results: The BanffNET TCMR/TI Index, AMR/MVI Index and Activity Index showed excellent discrimination of Banff TCMR, Banff MVI and Banff Any Diagnosis respectively, with validation AUCs ranging from 0.80 to 0.92. In addition, the BanffNET Indices explained large amounts of variability in multi-observer reference standards, time to graft failure and molecular biopsy-based diagnostics. In the large majority of cases, variability explained by BanffNET Indices matched or exceeded the variability explained by pathologist-assigned diagnoses and histological indices. Conclusions: BanffNET Indices are reproducible descriptors of whole slide images that could complement and augment kidney transplant biopsy evaluation by pathologists. Associations of BanffNET Indices with multi-observer diagnoses and related outcomes suggest that they capture additional information on tissue injury type and severity on top of pathologist-assigned Banff diagnoses and histological indices.

  • Open Access

    A multicenter kidney transplantation study identifies hierarchy and directionality of HLA-DQ alloimmune responses

    by Dennis A. J. Van Den Broek, Akansha Agrawal, Marta Crespo, Marie-Paule Emonds, Sebastiaan Heidt, Danny van der Helm, Tobias L. Lenz, Maria Meneghini, Eduard Palou, Dolores Redondo Pachón, et al.

    HLA-incompatibility between recipient and donor is conventionally assessed by counting serologic mismatches. More recently, tools quantifying differences at the amino acid level are advocated to prognosticate risk for generation of de-novo donor-specific antibodies (dnDSA). Using hierarchical clustering based on HLA evolutionary divergence and amino acid physiochemical unique qualities to evaluate HLA-DQ αβ-heterodimers, we demonstrate that HLA-DQ alleles segregate into two main evolutionary clades, and further subdivide into six functional sub-categories. Applying this biologically grounded immune risk-stratification approach to a cohort of 3003 kidney allograft recipients from five transplant centers shows that transplantation across the two evolutionary clades is associated with hierarchy and directionality of humoral immune responses, despite similar values when applying quantitative metrics. Our three-tier risk stratification model identifies patients at higher risk to develop dnDSA (HR:6.77; 95%CI:4.64-9.90), and antibody mediated rejection (HR:4.41; 95%CI:1.44-13.53). This work provides a thoughtful immunologic framework, that outperforms quantitative metrics, for alloimmune risk stratification.

  • Open Access

    Abdominal Erythema After Urinary Tract Infection: A Red Flag for Kidney Allograft Malakoplakia

    by Niels Schepens, Lorraine Belloy, Borefore P. Jallah, Dirk R.J. Kuypers, Priyanka Koshy, Mauricio Sainz Barriga, Maarten Naesens

  • Open Access

    Early acute T cell-mediated rejection and kidney allograft outcomes

    by Chuxiao Chen, Charbel Elias, Michelle Keyser, Karolien Wellekens, David M. Rothstein, Fadi G. Lakkis, Parmjeet Randhawa, Priyanka Koshy, Katharina A. Mayer, Matthias Diebold, et al.


  • Open Access

    Viewpoint on donor-derived cell-free DNA: Context of use and clinical utility are key

    by Klemens Budde, Georg A. Böhmig, Philip F. Halloran, Abhinav Humar, Anthony Langone, Maarten Naesens, Michael Oellerich, Rommel Ravanan, Tariq Shah, Ekkehard Schuetz, et al.


  • Open Access

    Immunosuppression-free Nonvascularized Rectus Fascia Allotransplantation for Complex Hernia Repair

    by Laurens J. Ceulemans, Ewout Muylle, Gert De Hertogh, Cedric Vanluyten, Antoine Dubois, Jan Van Slambrouck, Caroline Boelhouwer, Marina Gabriela M. C. Mori da Cunha, Ina Hennion, Antoine Weisrock, et al.

    Background.: Complex abdominal wall herniations present major reconstructive challenges, particularly in patients with contaminated fields or previous failed repairs. Synthetic meshes carry substantial infection risk, whereas biological meshes are expensive and exhibit inconsistent long-term strength, leaving many patients without dependable options. This study investigates the feasibility, safety, and immunologic profile of nonvascularized rectus fascia allotransplantation (NVRF-alloTx) for abdominal wall reconstruction in immunocompetent individuals. Methods.: We conducted a prospective single-center case series of 3 immunocompetent patients who underwent elective NVRF-alloTx between 2024 and 2025 at a tertiary academic hospital. Candidates had complex or contaminated defects that were unsuitable for synthetic or biologic mesh repair. Primary outcomes were durable abdominal wall closure, graft-related complications, and immunologic responses measured by donor-specific antibody screening. Secondary assessments included radiologic evaluation, biomechanical testing, histologic integration, and chimerism analysis in 1 patient whose graft was explanted postmortem. Results.: All patients achieved successful abdominal wall closure without hernia recurrence or graft failure during follow-up. Two developed de novo class I or II anti-HLA donor-specific antibodies. One patient died from unrelated cardiac disease 2 mo postoperatively; graft analysis demonstrated robust fibrovascular integration, limited T-cell infiltration, and biomechanical properties comparable to native fascia. Conclusion.: This early clinical experience demonstrates that NVRF-alloTx without immunosuppression can provide durable, mechanically stable abdominal wall reconstruction in high-risk immunocompetent patients. Despite measurable alloimmune sensitization, graft function remained intact. NVRF may represent a viable alternative in contaminated settings where traditional mesh-based strategies are contraindicated. Further study is needed to confirm long-term outcomes.


  • Clinical Relevance of Donor-Derived cfDNA In Monitoring Kidney Transplant Rejection

    by Angelica Pagliazzi, Karolien Wellekens, Henriette de Loor, Priyanka Koshy, Thibaut Vaulet, Arthur Vranken, Thomas Vanhoutte, Dirk Kuypers, Borefore Jallah, Tatjana Jatsenko, et al.

    Background: Over the past 25 years, donor-derived cell-free DNA (dd-cfDNA) has emerged as a noninvasive biomarker for detecting allograft rejection in kidney transplant recipients, yet its clinical interpretability and context(s) of use in post-transplant monitoring remain largely unexplored. Methods: In this observational cohort study, we analyzed 472 retrospective and 450 prospective plasma samples as the derivation and validation cohorts, respectively. Samples were collected at the time of either an indication or a protocol kidney biopsy. We evaluated three logistic regression models for rejection discrimination: a clinical model, the dd-cfDNA alone, and their combination. Result-specific likelihood ratios (LR) were derived from the dd-cfDNA-based model probabilities and applied to the clinical model predictions to obtain post-test probabilities of rejection. By comparing pre- and post-test probabilities, we assessed the impact of dd-cfDNA on rejection risk stratification. Results: Dd-cfDNA alone demonstrated strong discriminative ability, with AUCs of 0.79 (95% CI: 0.73–0.84) and 0.80 (95% CI: 0.72–0.87) in the derivation and validation cohorts, respectively. Combining dd-cfDNA with clinical parameters improved the above AUCs to 0.82 and 0.87, respectively. We compared pre- and post-test probabilities to determine how dd-cfDNA testing influenced rejection risk estimation. Incorporating dd-cfDNA-testing results clarified risk stratification by reducing the number of samples categorized as intermediate (10-30%) pre-test risk. Overall, 253/345 pre-test intermediate risk samples were reclassified, with 117/162 (72%) and 33/91 (36%) correctly assigned to low (≤10%) and high (≥30%) post-test risk, respectively. With 10% probability threshold for warranting a kidney biopsy, 482 biopsies would have been safely avoided using post-test probabilities, with 437 (91%) of these being protocol biopsies. Conclusions: Our study confirmed the strong association between dd-cfDNA% and rejection after kidney transplantation. Using test result-specific likelihood ratio, we evaluated the impact of integrating dd-cfDNA% for estimating time-point-specific rejection risk, demonstrating its potential to reduce the number of unnecessary biopsies in a cohort with a relatively low rejection prevalence.


  • Open Access

    Intragraft clonal expansion of cytotoxic CD8+ and CD4+ T cells in antibody-mediated kidney transplant rejection

    by Thibaut Vaulet, Baptiste Lamarthée, Jasper Callemeyn, Priyanka Koshy, Dany Anglicheau, Asier Antoranz, Tim Debyser, Bertrand Chauveau, Wilfried Gwinner, Dirk Kuypers, et al.


  • Open Access

    Cytomegalovirus Infection Determines Microvascular Inflammation Risk beyond Alloimmunity in Kidney Transplantation

    by Maarten Naesens, Thomas Vanhoutte, Matthias Diebold, Karolien Wellekens, Priyanka Koshy, Jasper Callemeyn, Bertrand Chauveau, Tim Debyser, Steffi De Pelsmaeker, Marie-Paule Emonds, et al.

    Microvascular inflammation (MVI) is a major determinant of kidney allograft failure, yet its upstream drivers remain incompletely defined. Natural killer (NK) cells contribute to donor-specific antibody (DSA)-positive and DSA-negative MVI via antibody-dependent cytotoxicity and missing-self recognition. Cytomegalovirus (CMV) infection durably remodels the NK cell compartment, inducing memory-like populations with heightened effector function. In a contemporary multicenter cohort of 4,411 kidney transplants with 10,214 post-transplant biopsies in the CMV prophylaxis era, CMV seropositivity, indicative of prior infection, was independently associated with a twofold higher hazard of MVI and increased graft failure. This association extended across antibody-mediated and DSA-negative, C4d-negative MVI and acted synergistically with HLA-DSA and missing self. Post-transplant CMV replication and disease were associated with subsequent MVI only in seronegative recipients, consistent with an effect of primary CMV infection. Together, these findings identify CMV infection as a clinically relevant and previously underrecognized determinant of MVI, beyond alloimmune factors.